All In Biotech

Drug Trial Radar · NCT06348290

Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects

a Single-center, Non-randomized, Open-label, Self-controlled Phase 1 Clinical Study to Evaluate Drug-drug Interactions of JMKX001899 Tablets in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

72

Planned (sponsor's estimate)

Start

Apr 1, 2024

Primary completion

May 31, 2024

Study completion Sep 15, 2024

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
First posted
Apr 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, non-randomized, clinical study to evaluate the drug interaction between itraconazole, rifampin or Cocktail and JMKX001899 in healthy subjects. A total of three cohorts of 72 healthy subjects were planned to be enrolled in each cohort.

Conditions

  • Solid Tumor, Adult

Interventions

  • JMKX001899Drug

    Oral

  • ItraconazoleDrug

    Oral

  • MidazolamDrug

    Oral

  • RifampinDrug

    Oral

  • dextromethorphanDrug

    Oral

  • RosuvastatinDrug

    Oral

  • digoxinDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. maximum concentrations (Cmax ) for plasmaTime frame: approximately 3 days after first dose
  2. area under the curve from time 0 to infinity(AUC0-inf) for plasmaTime frame: approximately 3 days after first dose
  3. area under the curve from time 0 to the last time point (AUC0-t) for plasmaTime frame: approximately 3 days after first dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.